MSB 1.50% $1.35 mesoblast limited

Ann: Ethics Approval to Treat COVID-19 Patients in Australia, page-131

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 5,344 Posts.
    lightbulb Created with Sketch. 960
    Australian ARDS trial .................................. Principal Investigator A/Prof. Tony Goldschlager said: “We are pleased that Monash Health is involved in this important COVID-19 trial, especially given the extensive experience we have had with Mesoblast’s mesenchymal lineage cells.”
    Why Prof. Tony Goldschlarger said this , because he was /is Principal investigator For Mesoblast in the Australian Arm of the CLBP trials With readouts now pending ......
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.35
Change
0.020(1.50%)
Mkt cap ! $1.547B
Open High Low Value Volume
$1.35 $1.40 $1.34 $3.562M 2.615M

Buyers (Bids)

No. Vol. Price($)
1 15000 $1.35
 

Sellers (Offers)

Price($) Vol. No.
$1.36 17969 2
View Market Depth
Last trade - 16.10pm 07/11/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.